What Will Puma Biotechnology Inc's $700 Million Man Do Next?
Brian Orelli, The Motley Fool - Motley Fool - Wed Jul 23, 6:21PM CDT
Alan Auerbach, CEO, president, and chairman of Puma Biotechnology , you just personally made over $700 million after your biotech suddenly soared 295% (more if you exercise all those warrants and options you have), what are you going to do now? ...
Most active New York Stock Exchange-traded stocks
AP - Wed Jul 23, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Wed Jul 23, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Why Do We Watch the Dow Jones So Closely When its Makeup Makes No Sense?
Alex Planes, The Motley Fool - Motley Fool - Wed Jul 23, 3:30PM CDT
The Dow Jones Industrial Average is a strange beast. With only 30 components, it can't possibly represent the scope of American stock markets as well as the broader S&P 500 . Yet not only does the Dow follow the S&P fairly closely in any...
Puma Biotechnology Stock Shoves It in Short Sellers' Faces
George Budwell, The Motley Fool - Motley Fool - Wed Jul 23, 3:01PM CDT
Biotech stocks are not for the faint of heart by any stretch of the imagination. Puma Biotechnology has repeatedly shown the investing world why this is the case, and today's 200% plus movement upward should drive this point home. PBYI ...
Why Puma Biotechnology Inc Stock More Than Tripled Today
Dan Carroll, The Motley Fool - Motley Fool - Wed Jul 23, 1:05PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Puma Biotechnology , a clinical-stage...
Puma Biotech Surges on Positive Results on Neratinib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 23, 12:41PM CDT
Shares of Puma Biotechnology, Inc. (PBYI) soared significantly after the company reported positive top-line results from the phase III trial on pipeline candidate, neratinib (PB272).
Midday Glance: Pharmaceuticals companies
AP - Wed Jul 23, 12:25PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Cubist Misses Q2 Earnings Estimates on Weak Cubicin Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 23, 12:10PM CDT
Cubist's (CBST) second quarter earnings were short of the Zacks Consensus Estimate.
Early Glance: Pharmaceuticals companies
AP - Wed Jul 23, 9:32AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Stock Market News for July 23, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Jul 23, 9:10AM CDT
Benchmarks settled in the green on Tuesday banking on encouraging housing data and upbeat corporate earnings results
Global Women's Health Market 2014-2018
M2 - Wed Jul 23, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kxqgp/global_womens) has announced the addition of the "Global Women's Health Market 2014-2018" report to their offering. The Global Women's Health market will grow at a CAGR of 3.52 percent over the period 2013-2018. Women experience physiological and emotional issues during different phases of their life cycle due to hormonal changes. Women's health is especially referred to where reproductive health is involved. According to the Society for Women's Health Research in the US, issues specific to the human female anatomy are defined as women's health. The biological mechanisms influence the clinical course of diseases and disorders differently in women when compared to men. Some of the main women's health disorders include infertility, menopause, endometriosis and polycystic ovarian syndrome as well as urological disorders and cancers such as breast cancer, cervical cancer, endometrial cancer, and ovarian cancer. In addition, contraception plays an important role in women's health for many reasons, so this too is also categorized under women's health. To calculate the market size, the report considers revenue generated from the sales of various products used for the wellbeing of women, which are listed below based on their application segment: - Postmenopausal Osteoporosis (Drugs) - Hormonal Contraceptives (Drugs and Devices) - Menopause (Drugs) - Infertility (Drugs) - Endometriosis (Drugs) - Polycystic Ovary Syndrome (Drugs) The report, the Global Women's Health Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA, and the APAC regions; it also covers the Global Women's Health market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actavis plc - Bayer AG - Eli Lilly and Co. - Merck & Co. - Pfizer Inc. According to the report, the growth of the Global Women's Health market is curtailed by some serious challenges. One of the main challenges is the patent expiry of major blockbuster drugs during the forecast period. Some of the patent expiries of top leading products include Bayer's Mirena and Yaz, Eli Lilly's Evista, and F. Hoffmann-La Roche's Boniva. For more information visit http://www.researchandmarkets.com/research/4k...bal_womens
Acquisition Agreements, Rejected Acquisition Tender Offers, Appointment, and Technical Updates - Research Reports on Pfizer, Gentiva, bluebird bio, Agios and AcelRx
PR Newswire - Wed Jul 23, 7:30AM CDT
Today, Analysts Review released its research reports regarding Pfizer Inc. (NYSE: PFE), Gentiva Health Services Inc. (NASDAQ: GTIV), bluebird bio, Inc. (NASDAQ: BLUE), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5013-100free.
Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - Wed Jul 23, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25
Puma Biotechnology Inc's Overnight Triple is Just the Beginning
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 22, 7:03PM CDT
Look at that cat go. Puma Biotechnology more than tripled in afterhours after announcing that its phase 3 trial testing neratinib in breast cancer patients was successful. The trial enrolled patients with early breast tumors having a mutation...
Johnson & Johnson Announces $5B Share Buyback - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 5:25PM CDT
Johnson & Johnson (JNJ) announced its plan to buy back up to $5 billion of its common stock.
Bayer/Regeneron Continue to Progress with Eylea - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 4:20PM CDT
Bayer (BAYRY) and Regeneron Pharmaceuticals (REGN) announced encouraging results from the phase III study on Eylea.